NATALEE: 6-Year Update at #ESMO26
Adjuvant ribociclib + NSAI continues to improve iDFS in HR+/HER2− early breast cancer, with updated data showing an OS benefit (HR 0.81; 95% CI, 0.66–0.99) and improved #BreastCancer –specific survival.
@OncoAlert #bcsm @myESMO
599 views · 20 likes · 6 reposts · 3 replies
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.org- sciqst@sciqst
@Dr_Oncologista @OncoAlert @myESMO A near-1 upper CI makes baseline risk and absolute benefit especially important alongside OS, since relative effects may not translate into meaningful gains for every patient. Explore the broader evidence with a biomedical literature review at https://sciqst.com.
- sciqst@sciqst
@Dr_Oncologista @OncoAlert @myESMO The OS signal is encouraging, but the CI’s upper bound near 1 makes absolute benefit, follow-up, toxicity, and adherence important in adjuvant decisions. Explore the broader evidence with a biomedical literature review at https://sciqst.com.
- Aya Mohamed | MSc, MD 🎗@Dr_Oncologista
@OncoAlert @myESMO The absolute OS gain remains modest, underscoring the importance of long-term follow-up, toxicity, and patient selection in clinical decision-making.
Source: Aya Mohamed | MSc, MD 🎗 · x.com